Estradiol phenylpropionate

Estradiol phenylpropionate
Clinical data
Trade names	Menformon Prolongatum, Dimenformon Prolongatum, Lynandron Prolongatum
Other names	Estradiol phenpropionate; Estradiol benzenepropionate; Estradiol phenylpropanoate; Estradiol benzenepropanoate
Routes of; administration	Intramuscular injection
Drug class	Estrogen; Estrogen ester
Identifiers
	IUPAC name [(8R,9S,13S,14S,17S)-3-Hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-phenylpropanoate;
CAS Number	26443-03-8;
PubChem CID	68577;
ChemSpider	61847;
UNII	LS956OGN6U;
ChEMBL	ChEMBL1974118;
CompTox Dashboard (EPA)	DTXSID00181040 ;
ECHA InfoCard	100.043.340
Chemical and physical data
Formula	C27H32O3
Molar mass	404.550 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC12CCC3C(C1CCC2OC(=O)CCC4=CC=CC=C4)CCC5=C3C=CC(=C5)O;
	InChI InChI=1S/C27H32O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,9,11,17,22-25,28H,7-8,10,12-16H2,1H3/t22-,23-,24+,25+,27+/m1/s1; Key:LQWSQQKTZLDGME-RYIFMDQWSA-N;

Estradiol phenylpropionate (EPP), also known as estradiol 17β-phenylpropionate and sold under the brand name Menformon Prolongatum, is an estrogen which is no longer marketed. It is an estrogen ester, specifically the C17β phenylpropionate ester of estradiol.

EPP has been marketed in combination with estradiol benzoate under the brand name Dimenformon Prolongatum in Europe and in combination with estradiol benzoate, testosterone propionate, testosterone phenylpropionate, and testosterone isocaproate under the brand names Mixogen, Estandron Prolongatum, and Lynandron Prolongatum (a balanced mixture of estradiol and testosterone esters) in menopausal hormone therapy. Both of these medication combinations are long-acting injectables indicated in hormone replacement therapy for women in menopause. Dimenformon Prolongatum has also been investigated as a single injection, "morning after" post-coital contraceptive, and is additionally used as a component of hormone replacement therapy for transgender women.

The pharmacokinetics of EPP in combination with estradiol benzoate have been studied.